HOME >> MEDICINE >> NEWS
Penn researchers find that chronic dizziness may be caused by psychiatric and neurologic illnesses

Approximately 9 million to 15 million people in the U.S. suffer from recurrent bouts of dizziness and 3 million experience symptoms of dizziness nearly every day. According to a paper that appears in the February issue of Archives of OtolaryngologyHead & Neck Surgery, researchers at the University of Pennsylvania School of Medicine found that chronic subjective dizziness (CSD) may have several common causes, including anxiety disorders, migraine, mild traumatic brain injuries, and neurally mediated dysautonomias disorders in the autonomic nervous system, which controls involuntary actions.

Among the various forms of dizziness, clinicians have found CSD to be particularly vexing. "Patients with CSD experience persistent dizziness not related to vertigo, imbalance, and hypersensitivity to motion, which is heightened in highly visual settings, such as walking in a busy store or driving in the rain," says Jeffrey P. Staab, MD, MS, Assistant Professor, Departments of Psychiatry and Otorhinolaryngology at Penn, and coauthor of the paper.

Staab and coauthor, Michael J. Ruckenstein, MD, Associate Professor Department of Otorhinolaryngology at Penn, studied 345 men and women age 15 to 89 (average age 43.5) who had dizziness for three months or longer due to unknown causes. From 1998 to 2004, the patients were tracked from their referral to Penns balance center through multiple specialty examinations until they were given a diagnosis.

"All but six patients were diagnosed as having psychiatric or neurologic conditions, including primary or secondary anxiety disorders, migraine, traumatic brain injury and neurally mediated dysautonomias," said Ruckenstein. Most patients (59.7%) had CSD with anxiety, 38.6% had CSD and illnesses of the central nervous system (migraine, traumatic brain injuries, or dysautonomias), and 1.7% had CSD and irregular heartbeats.

Two-thirds of patients had medical conditions associated with the onse
'"/>

Contact: Kate Olderman
kate.olderman@uphs.upenn.edu
215-349-8369
University of Pennsylvania School of Medicine
20-Feb-2007


Page: 1 2

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
3. Penn researchers discover novel pathway for increasing good cholesterol
4. Theory of facial aging gets a facelift from UT Southwestern researchers
5. UIC researchers to develop new drugs to fight bioterrorism
6. UQ researchers discover some of the oldest forms of life
7. U of M researchers discover new method to combat HIV
8. U of M researchers assess effectiveness of computerized physician order entry system
9. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
10. Physician-researchers often less successful in obtaining NIH funding
11. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells

Post Your Comments:
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: